CD262, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD262, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD262, Human |
| Clone | DJR2-4 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1κ |
| Format | biotin conjugate |
| Size | 100 tests in 1 mL |
| Concentration | 1:11 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD262 Antibody, anti-human, Biotin. The DJR2-4 antibody binds to death receptor 5 (DR5), member 10B of the TNF receptor superfamily (TNFRSF10B), also known as CD262, TRAIL-R2/ TRAILR2, TRICK2, KILLER, and ZTNFR9. Binding of TNF-related apoptosis-inducing ligand (TRAIL, TNFSF10, TL2, APO2L, Apo-2L) to DR5 induces apoptosis via the intracellular adaptor molecule FADD/MORT. The DR5 receptor is broadly expressed on many tumors and normal tissues. DR5 expression is upregulated by interferon α, taxotere, and paclitaxel, making DR5+ target cells more susceptible to NK cell mediated killing. |
| Immunogen | n/a |
| Other Names | TNFRSF10B, DR5, KILLER, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9 |
| Gene, Accession # | Gene ID: 8795 |
| Catalog # | 130-097-303 |
| Price | $264 |
| Order / More Info | CD262, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Sato, K. et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174 (7): 4025-4033. | Uno, K. et al. (2003) TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101 (9): 3658-3667. | Walczak, H. et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (17): 5386-5397. | LaVallee, T. M. et al. (2003) 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 (2): 468-475. | Nimmanapalli, R. et al. (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 62 (2): 759-763. | Qiu, Y. et al. (2007) The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 67 (10): 4973-4980. | Cheent, K. and Khakoo, S. I. (2011) Natural killer cells and hepatitis C: action and reaction. Gut 60 (2): 268-278. | MacFarlane, M. et al. (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272 (41): 25417-25420. | Gajate, C. and Mollinedo, F. (2005) Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 280 (12): 11641-11647. | Shigeno, M. et al. (2003) Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22 (11): 1653-1662. | Stolfi, C. et al. (2011) 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol. Cancer Ther. 10 (10): 1969-1981. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies